Serum matrix metalloproteinase-2 in patients with malignant melanoma

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue 10, 2001, Pages 631-635

  Wollina, Uwe ^a,b   Hipler, Uta Christina ^a   Knöll, Brunhilde ^a   Graefe, Tim ^a   Kaatz, Martin ^a   Kirsch, Karsten ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Malignant melanoma; Matrix metalloproteinase 2; Tumor markers

Indexed keywords

GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN S 100; PROTEIN S 100BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CORRELATION FUNCTION; ENZYME ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0034884705     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320100257     Document Type: Article

References (32)

1. Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma
2. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhances cellular invasion by melanoma cells
3. Serological markers for melanoma
4. Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential
5. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma
6. Serum levels of sICAM-1 and 5-cysteinyldopa as markers of melanoma progression
7. Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression
8. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression
9. Coexpression of integrin avb3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: Correlation with melanoma progression
10. Characterization of a liver metastatic variant of murine K1735M2 melanoma cells
11. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma
12. Matrix metalloproteinases and metastasis
13. Matrix metalloproteinases and their inhibitors
14. Mechanisms of metastasis
15. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines
16. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
17. Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways
18. Transmembrane/cytoplasmic domain-mediated membrane type 1-metalloprotease docking to invadopodia is required for cell invasion
19. Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Stand 1993/94
20. Matrix metalloproteinases in wound repair
21. Circulating adhesion molecules as prognostic factors for cutaneous melanoma
22. Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron-microscopic study including immunoelectron microscopy
23. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
24. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value
25. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma
26. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma
27. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma
28. Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma
29. Simultaneous measurement of circulating intercellular adhesion molecule-I and serum copper zinc dismutase activity in patients with malignant melanoma
30. Soluble ICAM-1 seems to be related to prognosis in malignant melanoma
31. Serum protein S-100beta in patients with malignant melanoma detected by an immuno-luminometric assay
32. Serum metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases- 1, -2 in lung cancer - TIMP-1 as a prognostic marker